Abstract
As the director of one of the largest evaluation and treatment centers for patients with aspirin-exacerbated respiratory disease (AERD) in the world, I am often asked on how we should approach the use of aspirin desensitization followed by high-dose aspirin therapy for our patients with AERD in the current age of newly available biologics. I feel strongly that, at least for now, there is a place for both treatment modalities, sometimes even both in the same patient at the same time. In the end, it is always a set of decisions that need to be made on an individual patient basis, and I consider the following 4 general domains when approaching the decision and my recommendation: efficacy, safety, cost, and patient preference.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
